NASDAQ:OPHT IVERIC bio (OPHT) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free OPHT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.13▼$1.3952-Week Range N/AVolumeN/AAverage Volume159,109 shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IVERIC bio alerts: Email Address Ad Crypto Swap ProfitsGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About IVERIC bio Stock (NASDAQ:OPHT)IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here OPHT Stock News HeadlinesNovember 5, 2023 | morningstar.comGossamer Bio Inc GOSSJune 30, 2023 | msn.comIveric Bio ticks higher as it sees sale to Astellas closing July 11March 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.June 29, 2023 | msn.comIveric Bio falls amid concern about Astellas dealMay 6, 2023 | msn.comBaird Downgrades IVERIC bio (ISEE)May 6, 2023 | msn.comApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioMay 2, 2023 | msn.comIveric Bio (NASDAQ:ISEE) Sold for $5.9BMay 1, 2023 | msn.comAstellas to Buy Eye-Drug Maker Iveric Bio for $5.9 BillionMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMay 1, 2023 | reuters.comAstellas Pharma buys Iveric Bio for $5.9 billionApril 30, 2023 | msn.comAstellas Pharma to Buy Iveric Bio for $5.9 BillionApril 30, 2023 | wsj.comAstellas Pharma to Buy Iveric Bio for About $5.9BApril 30, 2023 | msn.comAstellas Pharma agrees to buy Iveric Bio for $5.9 BillionMarch 3, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)March 1, 2023 | marketwatch.comIVERIC Bio Shares Up 14% After Positive Trial Results, 4Q LossesFebruary 17, 2023 | marketwatch.comIveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad PegolFebruary 16, 2023 | nasdaq.comDeep Track Capital Now Owns 5.88% of IVERIC bio (ISEE)February 16, 2023 | nasdaq.comRtw Investments Now Owns 0.60% of IVERIC bio (ISEE)September 16, 2022 | seekingalpha.comISEE IVERIC bio, Inc.September 7, 2022 | markets.businessinsider.comWhere IVERIC bio Stands With AnalystsAugust 25, 2022 | markets.businessinsider.comIveric Bio To Announce GATHER2 Trial Data In SeptemberJanuary 18, 2022 | thestreet.comWhy Ophthotech (OPHT) Stock Is Surging TodayAugust 9, 2021 | seekingalpha.comIVERIC bio, Inc. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive OPHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2018Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OPHT CUSIPN/A CIK1410939 Webwww.ophthotech.com Phone(212) 845-8200FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$63.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.53% Return on Assets-41.88% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09 Sales & Book Value Annual Sales$209.98 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / BookN/AMiscellaneous Outstanding Shares41,420,000Free FloatN/AMarket Cap$1.65 billion OptionableOptionable Beta1.49 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesGlenn P. SblendorioPresident, Chief Executive Officer & DirectorKeith WestbyChief Operating Officer & Senior Vice PresidentDavid F. CarrollChief Financial Officer, Treasurer & SVPKourous A. RezaeiChief Medical Officer & Senior Vice PresidentAbraham ScariaChief Scientific OfficerKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOProtagonist TherapeuticsNASDAQ:PTGXMorphicNASDAQ:MORFDynavax TechnologiesNASDAQ:DVAXEdgewise TherapeuticsNASDAQ:EWTXView All Competitors OPHT Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:OPHT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.02. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC). This page (NASDAQ:OPHT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.